253 related articles for article (PubMed ID: 30149766)
1. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
3. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.
Rafei-Shamsabadi D; Lehr S; von Bubnoff D; Meiss F
Cancer Immunol Immunother; 2019 Sep; 68(9):1417-1428. PubMed ID: 31422446
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
[TBL] [Abstract][Full Text] [Related]
5. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Wang XY; Zuo D; Sarkar D; Fisher PB
Expert Opin Pharmacother; 2011 Dec; 12(17):2695-706. PubMed ID: 22077831
[TBL] [Abstract][Full Text] [Related]
6. Melanoma immunotherapy.
Sanlorenzo M; Vujic I; Posch C; Dajee A; Yen A; Kim S; Ashworth M; Rosenblum MD; Algazi A; Osella-Abate S; Quaglino P; Daud A; Ortiz-Urda S
Cancer Biol Ther; 2014 Jun; 15(6):665-74. PubMed ID: 24651672
[TBL] [Abstract][Full Text] [Related]
7. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
[TBL] [Abstract][Full Text] [Related]
8. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
Barker CA; Postow MA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of melanoma.
Lacy KE; Karagiannis SN; Nestle FO
Clin Med (Lond); 2012 Apr; 12(2):168-71. PubMed ID: 22586796
[No Abstract] [Full Text] [Related]
10. Immune based therapy for melanoma.
Ancuceanu R; Neagu M
Indian J Med Res; 2016 Feb; 143(2):135-44. PubMed ID: 27121512
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for melanoma: current status and perspectives.
Alexandrescu DT; Ichim TE; Riordan NH; Marincola FM; Di Nardo A; Kabigting FD; Dasanu CA
J Immunother; 2010; 33(6):570-90. PubMed ID: 20551839
[TBL] [Abstract][Full Text] [Related]
12. Melanoma: An update on systemic therapies.
Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Immune Evasion in Melanoma.
Eddy K; Chen S
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256089
[TBL] [Abstract][Full Text] [Related]
14. Are patients in haemodialysis good candidates for immunotherapy treatment?
Fernandez-Diaz AB; Cunquero-Tomas AJ; Garcia-Medina A; Ferrer-Guillen B; Berrocal A
Melanoma Res; 2019 Oct; 29(5):553-555. PubMed ID: 31464825
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory cytokines as therapeutic agents for melanoma.
Nicholas C; Lesinski GB
Immunotherapy; 2011 May; 3(5):673-90. PubMed ID: 21554095
[TBL] [Abstract][Full Text] [Related]
16. Optimal management of metastatic melanoma: current strategies and future directions.
Batus M; Waheed S; Ruby C; Petersen L; Bines SD; Kaufman HL
Am J Clin Dermatol; 2013 Jun; 14(3):179-94. PubMed ID: 23677693
[TBL] [Abstract][Full Text] [Related]
17. State of Melanoma: An Historic Overview of a Field in Transition.
Karapetyan L; Kirkwood JM
Hematol Oncol Clin North Am; 2021 Feb; 35(1):1-27. PubMed ID: 33759768
[TBL] [Abstract][Full Text] [Related]
18. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy of cancer-clinical perspectives.
Majidpoor J; Mortezaee K
Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
[TBL] [Abstract][Full Text] [Related]
20. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
Henning A; Agnese D; Chung CG
J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]